Study: Gene variant affects response to bowel cancer drugs

10/23/2008 | Bloomberg · Yahoo!

Advanced colon cancer patients with a mutation in the BRAF gene do not respond to ImClone Systems' Erbitux and Amgen's Vectibix, Italian researchers reported. The finding comes after earlier studies showed that another gene called KRAS can help identify patients who are most likely to benefit from both drugs.

View Full Article in:

Bloomberg · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD